Product Name: Estradiol valerate

CAS: 979-32-8

Standard: Enterprise Standard

Natural / Synthetic: Synthetic

Level: Medical grade

Content: 99%

Appearance: white powder

Packing: 1KG/aluminum foil bag detachable

 Direct export

Physical and chemical properties: white crystalline powder; odorless. This product is soluble in ethanol, acetone or chloroform, dissolved in methanol, slightly soluble in vegetable oil, and almost insoluble in water.

Category: Chemical raw materials

Industry: Chemical Materials

Field: Estrogen

Lower product: Estradiol valerate tablets, sustained release tablets

Use: 1. Correct the symptoms caused by estrogen deficiency and estrogen deficiency, such as unstable vasomotor symptoms, urogenital atrophy, neuropsychiatric symptoms in women with natural or artificial menopause. 2. Postmenopausal women maintain bone density, prevent or delay the occurrence of osteoporosis; protect the cardiovascular system and reduce the risk of arteriosclerotic cardiovascular disease. 3. Amenorrhea patients at the childbearing age artificially induce menstrual cramps to prevent genital atrophy. 4. Promote the development of breast, secondary sexual and reproductive tract in primary amenorrhea patients. 5. Advanced prostate cancer. 6. In combination with progestogen drugs, it can inhibit ovulation and can be used as a contraceptive. 7. For retreat.

Dosage: 1. (1) Insufficient estrogen supplement: 5mg each time, once every 4 weeks; (2) Prostate cancer: 30mg each time, once every 1~2 weeks, adjust the dosage as needed; (3) Replace Treatment: 5 to 10 mg each time, once every 1 to 2 weeks. The average is 5 to 20 mg every 2 weeks; (4) the retreat: 10 mg each time. 2. Oral administration: Estradiol valerate sustained release tablets 1 to 2 mg per day for 20 consecutive days. The amount of estradiol valerate tablets varies from person to person. The general dose is 1 ~ 2mg per day, swallowed with water after meals, for 25 to 28 days. Patients with a complete uterus need to add progesterone for 10 to 14 days on the 15th to 19th day of taking the drug. There should be menstrual bleeding for several days within 2 weeks of withdrawal. It can be taken repeatedly in the same way from the fifth day of bleeding. This program is called a “periodic sequential approach” and is suitable for premenopausal women and women who require menstrual cramps after menopause. For women who do not want menstruation more than 1 year after menopause, the "continuous joint program" can be used, that is, taking female and progesterone at the same time every day without interruption. The initial dose can be 1mg per day of estradiol valerate tablets. Treat the reaction and make the necessary adjustments.